


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231



On March 18, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Kathryn A. Deglarien

**PATENT**  
Attorney Docket No.: 019916-003810US  
Client Reference No.: 0009

1651

**RECEIVED**

APR 01 2002

TECH CENTER 1600/2900

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Stephen A. Empedocles, et al.

Application No.: 09/882,193

Filed: June 13, 2001

For: SINGLE TARGET COUNTING  
ASSAYS USING SEMICONDUCTOR  
NANOCRYSTALS

Examiner:

Art Unit: 1651

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the United States patents, which are readily available to the Examiner, are not enclosed. Applicant would be glad to furnish copies of the U.S. Patents if the Examiner so desires. All of the non-patent references are enclosed. Also enclosed is a copy of an International Preliminary Examination Report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Jeffry S. Mann  
Reg. No. 42,837

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
JSM:kad

SF 1326219 v1

PATENT COOPERATION TREATY  
**PCT**

01/01/348

INTERNATIONAL PRELIMINARY EXAMINATION REPORT  
(PCT Article 36 and Rule 70)

Applicant's or agent's file reference  19916-38PC	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No.  PCT/US01/05164	International filing date (day/month/year)  16 February 2001 (16.02.2001)	Priority date (day/month/year)  16 February 2000 (16.02.2000)	
International Patent Classification (IPC) or national classification and IPC  IPC(7): G01N 33/533 and US Cl.: 435/7.1			
Applicant  QUANTUM DOT CORPORATION			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>4</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of <u>0</u> sheets.</p> <p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input checked="" type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand  22 August 2001 (22.08.2001)	Date of completion of this report  07 November 2001 (07.11.2001)		
Name and mailing address of the IPEA/US  Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230	<p>Authorized officer  Bao-Thuy L. Nguyen </p> <p>Telephone No. (703) 308-0196</p>		

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US01/05164

**I. Basis of the report**

## 1. With regard to the elements of the international application:\*

 the international application as originally filed. the description:

pages 1-58 as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the claims:

pages 59-64, as originally filed

pages NONE, as amended (together with any statement) under Article 19pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the drawings:

pages 1-12, as originally filed

pages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_ the sequence listing part of the description:pages NONE, as originally filedpages NONE, filed with the demandpages NONE, filed with the letter of \_\_\_\_\_

## 2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

## 3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4.  The amendments have resulted in the cancellation of: the description, pages NONE the claims, Nos. NONE the drawings, sheets/fig NONE5.  This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).\*\*

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

**V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. STATEMENT**

Novelty (N)	Claims <u>1-39</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-39</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-39</u>	YES
	Claims <u>NONE</u>	NO

**2. CITATIONS AND EXPLANATIONS**

Claims 1-39 meet the criteria set out in PCT Article 33(2)-(4), because the prior art does not teach or fairly suggest a method of detecting a target species using two different single quantum dots as label.

----- NEW CITATIONS -----

Chan et al., Quantum Dot Bioconjugates for Ultrasensitive Nonisotopic Detection. Science. Vol. 281. 1998. Pages 2016-2018.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/US01/05164

## VI. Certain documents cited

## 1. Certain published documents (Rule 70.10)

Application No Patent No.	Publication Date (day/month/year)	Filing Date (day/month/year)	Priority date (valid claim) (day/month/year)
6,207,392 B1	27 March 2001 (27.03.2001)	01 March 1999 (01.03.1999)	None
6,114,038 A	05 September 2000 (05.09.2000)	11 August 1999 (11.08.1999)	None
6,306,610 B1		17 September 1999 (17.09.1999)	None
6,287,768 B1	23 October 2001 (23.10.2001)		None
6,274,323 B1	11 September 2001 (11.09.2001)	03 March 2000 (03.03.2000)	None
	14 August 2001 (14.08.2001)	05 May 2000 (05.05.2000)	

## 2. Non-written disclosures (Rule 70.9)

Kind of non-written disclosure	Date of non-written disclosure (day/month/year)	Date of written disclosure referring to non-written disclosure (day/month/year)